Antibiotic Apocalypse: Resistance is (Not) Futile
Threatening global economies, healthcare systems and human lives, the issue of antibiotic resistance is ever-present. But how much closer are we to resolving the problem?
Maryam Mahdi | | Longer Read
Antimicrobial resistance (AMR) affects societies across the world. Each year, an estimated 700,000 people die worldwide as a result of drug resistant bacterial infections (1). The repercussions for public health are clear – but there are also economic implications; estimates suggest that 3.8 percent of the world’s annual GDP could be lost by 2050 in a high-AMR scenario (where a significant number of antibiotics fail to treat bacterial infections) with an annual loss of $3.4 trillion by 2030 (2).
The solution to this far-reaching issue? Well, it is far from straightforward. There may well be a pressing need to regenerate a sustainable pipeline of new drugs to combat AMR, but Andrew Edwards, a senior lecturer at Imperial College London, argues that current market conditions aren’t suited to the development of antibiotics.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.